Type 1 diabetes is becoming a peptide-and-protein therapeutic territory beyond insulin. The 2026 storyline runs across three approaches: disease-modifying immunotherapy via teplizumab, beta-cell preservation via small-molecule menin inhibitors, and GLP-1 cardiovascular and kidney protection in T1D patients with elevated risk.
Key developments covered here: Sanofi's Tzield (teplizumab) won FDA approval for children down to age 1 in Stage 2 T1D — the first disease-modifying therapy in pediatric T1D. A Johns Hopkins study published in early 2026 reported GLP-1 receptor agonists reduced cardiovascular and kidney events in T1D patients. Biomea Fusion's icovamenib COVALENT-112 52-week Phase 2 readout (April 27) showed a 52% C-peptide AUC increase at Week 12 in newly diagnosed T1D, persisting through Week 52 after only 12 weeks of dosing.
Stories here cover trial readouts, regulatory milestones, and the broader peptide-pathway therapeutic landscape in T1D. See #c-peptide, #beta-cell, and #glp-1.
Biomea Fusion announced April 27 positive 52-week Phase 2 COVALENT-112 results in newly diagnosed type 1 diabetes. Patients diagnosed within 0–3 years dosed with icovamenib 200 mg once daily for 12 weeks showed a 52% increase in mean C-peptide AUC at Week 12 (p<0.001, n=5), with persistence through Week 52 (only ~7% decline from baseline) following just 12 weeks of dosing. C-peptide preservation was also observed in patients diagnosed 3–15 years prior (n=9). Icovamenib, a covalent menin inhibitor, was generally well tolerated with no new safety signals. Biomea is planning a Phase 2 expansion at four US academic centers in H2 2026 evaluating extended dosing (6 or 12 months) at 200 mg, with potential addition of an immunosuppressive agent. The data shifts attention back to beta-cell preservation as a T1D therapeutic strategy.
Sanofi announced April 22 FDA approval of an expanded Tzield (teplizumab-mzwv) indication for stage 2 type 1 diabetes patients as young as 1 year old, down from the previous 8-and-up indication. The approval was supported by 1-year data from the PETITE-T1D Phase 4 study (n=23, mean age 4.8 years), showing 89.6% probability of remaining stage-3-progression-free at 1 year. Tzield delays progression from stage 2 to stage 3 T1D by an average of 2 years and is the first disease-modifying therapy for autoimmune T1D — relevant to the broader insulin/peptide endocrinology landscape.
A study of ~175,000 Type 1 diabetes patients found GLP-1 receptor agonists reduced five-year cardiovascular event risk by 15% and end-stage kidney disease by 19%, with no increase in severe hypoglycemia. Published in Nature Medicine.